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The orthopoxvirus serpin SPI-3 is N-glycosylated and suppresses fusion between infected cells. Although SPI-3 contains
motifs conserved in inhibitory serpins, no proteinase inhibition by SPI-3 has been demonstrated, and mutations within the
serpin reactive center loop (RCL) do not affect the ability to regulate cell fusion. We demonstrate here that SPI-3 protein
expressed by transcription/translation in vitro is able to form SDS-stable complexes with the serine proteinases plasmin,
urokinase-type plasminogen activator (uPA), and tissue-type plasminogen activator (tPA), consistent with inhibitory activity of
the serpin. Weaker complexes were noted with factor Xa and thrombin. Mutation of Arg-340/Ser-341 at the predicted P1/P19
sites within the RCL prevented the formation of complexes between SPI-3 and plasmin, uPA, or tPA, suggesting that the
arginine at the P1 position was required for complex formation. SPI-3 protein lacking the N-terminal signal peptide was
purified by means of an N-terminal His10-tag and gave complete inhibition in vitro of plasmin, uPA, and tPA and partial
inhibition of factor Xa. SPI-3 is therefore a bifunctional protein that acts as a proteinase inhibitor and suppresses infected
cell–cell fusion. As a proteinase inhibitor, SPI-3 has similar specificity to the leporipoxvirus SERP1 protein of myxoma virus,
although the two serpins are less than 30% identical overall. The inhibition constants of SPI-3 for plasmin, uPA, and tPA were
determined to be 0.64, 0.51, and 1.9 nM, respectively, very similar to the corresponding K i values of SERP1. © 2000 Academic
PressINTRODUCTION
The poxvirus family comprises a large and morpholog-
ically complex group of viruses (Moss, 1996), with a
broad collective host range (Fenner, 1996). Poxvirus ge-
nomes encode a number of proteins that counteract the
host’s immune defenses, including soluble receptors for
proinflammatory cytokines and chemokines and proteins
that interfere with cytokine metabolism (Nash et al., 1999;
Pickup, 1994; Smith et al., 1997). Included in this category
of proteins that are nonessential for growth in tissue
culture are the poxvirus serpins (Turner et al., 1995),
members of the superfamily of serine proteinase inhibi-
tors that are found in plants, animals, and insects (Po-
tempa et al., 1994). Mammalian serpins are best known
as abundant plasma proteins that regulate coagulation,
fibrinolysis, complement activation, and inflammation
(Carrell and Boswell, 1986; Potempa et al., 1994). Defi-
ciencies in serpins result in a number of human diseases
including emphysema, cirrhosis, angioedema, and
thrombotic diseases (Potempa et al., 1994). Serpins are
also involved in tumor metastasis (Pemberton, 1997) and
in inhibiting misdirected granzyme B and cathepsin G
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267within cells (Bird et al., 1998; Scott et al., 1999). Inhibitory
serpins are pseudo-substrates that form very stable 1:1
complexes with their cognate proteinases (Carrell et al.,
1987). The crucial determinant of specificity in inhibitory
serpins is the P1 residue within the exposed reactive
center loop (RCL) near the C-terminus (Potempa et al.,
1994). However, some serpin family members do not
function as proteinase inhibitors, but instead have other
biological roles such as hormone transport and regula-
tion of angiogenesis (Potempa et al., 1994).
To date, the only viruses that encode functional full-
length serpins are the poxviruses (Turner et al., 1995). The
orthopoxviruses encode three serpins, of which the best
characterized is crmA, also known as SPI-2. CrmA can
inhibit cysteine proteinases such as caspases, including
ICE (interleukin-1b converting enzyme, caspase-1) (Ray et
al., 1992; Komiyama et al., 1994) and caspase-8 (Zhou et al.,
1997), and has anti-inflammatory and anti-apoptotic activity
(Cohen, 1997). crmA also inhibits the serine proteinase
granzyme B (Quan et al., 1995) and reduces killing by
cytotoxic T-lymphocytes (Macen et al., 1996; Tewari et al.,
1995). The orthopoxvirus SPI-1 protein shares 45% identity
with crmA/SPI-2, is required for full host range of rabbitpox
virus (Brooks et al., 1995), and has recently been shown to
form a stable complex with cathepsin G (Moon et al., 1999).
For both crmA/SPI-2 and SPI-1, their biological properties
can be ascribed to their ability to act as proteinase inhibi-
tors.
0042-6822/00 $35.00
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268 TURNER ET AL.The remaining orthopoxvirus serpin SPI-3 is re-
quired to prevent cell–cell fusion following infection
(Law and Smith, 1992; Turner and Moyer, 1992; Zhou et
l., 1992) and is present in cowpox virus (CPV) and
accinia virus (VV). SPI-3 from infection with wtCPV
as an apparent size of 50 kDa by SDS–PAGE (Turner
nd Moyer, 1995), in contrast with the expected size of
2 kDa for the primary translation product of vaccinia
irus SPI-3 (Boursnell et al., 1988). Based on a reduc-
tion of the apparent size of SPI-3 in the presence of the
inhibitor tunicamyin, SPI-3 appears to have extensive
N-linked glycosylation (Turner and Moyer, 1995). SPI-3
resembles the poxvirus hemagglutinin (Ichihashi and
Dales, 1971) in that both viral gene products are gly-
coproteins, and inactivation of either gene results in
cell–cell fusion following infection. Inhibition of fusion
by SPI-3 does not require the conserved serpin motifs
present in this protein, as site-directed mutants in the
RCL were fully functional in suppressing cell fusion
(Turner and Moyer, 1995). By alignment of the SPI-3
RCL with other serpins, the predicted P1 residue of
SPI-3 is arginine. Although SPI-3 has not been shown
to function as a serpin, one might expect the biochem-
ical properties of SPI-3 to resemble those of the myx-
oma virus (MYX) SERP1, a serpin that also has a P1
Arg residue. SERP1 has been shown to inhibit the
human serine proteinases plasmin and urokinase- and
tissue-type plasminogen activators in vitro (Lomas et
al., 1993), as well as thrombin and factor Xa (Nash et
al., 1998). MYX SERP1 is a potent virulence factor in
both malignant rabbit fibroma virus (Upton et al., 1990)
and MYX (Macen et al., 1993), and it has anti-inflam-
matory activity within the context of wtMYX infection
(Macen et al., 1993). SERP1 protein added exog-
enously can block inflammation in an animal model for
arthritis (Maksymowych et al., 1996) and prevents the
development of atherosclerotic plaque after balloon
angioplasty in rabbits and pigs (Lucas et al., 1996).
SERP1, like SPI-3, is an N-glycosylated protein and is
the only naturally secreted poxvirus serpin (Macen et
al., 1993). SPI-3 is expressed early prior to DNA repli-
cation (Smith et al., 1989; Turner and Moyer, 1995) but
ERP1 is synthesized late (Macen et al., 1993).
Prior to the current study there was no indication
hat SPI-3 inhibited any proteinases. By screening a
anel of proteinases for their ability to complex with
PI-3, we found that SPI-3 can form stable complexes
ith plasmin, uPA, and tPA. Purified SPI-3 protein in-
ibits the same proteinases in enzymatic assays, and
PI-3 is therefore a functional inhibitory serpin and
cts as a suppressor of cell fusion. Despite consider-
ble sequence divergence between SPI-3 and SERP1,he inhibitory profile of SPI-3 is similar to that of
ERP1. aRESULTS
equence comparison between CPV SPI-3 and MYX
ERP1
The nucleotide sequence was determined for the
PI-3 gene of the Brighton Red strain of CPV and has
een deposited with GenBank (Accession No.
F216779). Each of the nucleotide and deduced amino
cid sequences for the Brighton Red strain of CPV SPI-3
as 97% identical to the corresponding sequence of the
PI-3 from CPV strain GRI-90 (Shchelkunov et al., 1998).
s expected, the CPV SPI-3 protein is very similar to the
orresponding proteins from other orthopoxviruses such
s vaccinia (Goebel et al., 1990), variola (Massung et al.,
993), and ectromelia viruses, with 94, 95, and 94% iden-
ity, respectively. An alignment of the CPV SPI-3 protein
ith the leporipoxvirus MYX SERP1 protein is shown in
ig. 1. Overall the identity between the two proteins is
nly 29.4%, which is similar to the degree of identity seen
etween any two members of the serpin superfamily. In
omparison, CPV SPI-3 is 30.4% identical to plasminogen
ctivator inhibitor-1 (PAI-1) precursor, and SERP1 is 36%
dentical to PAI-1. SERP1 is therefore more similar to the
ammalian serpin PAI-1 than to the viral serpin SPI-3. By
tudying the phylogenetic relationships between serpins
nd assigning them to clades, SERP1 and SPI-3 have
een shown to belong to distinct groups (James Irving,
onash University, Melbourne, Australia, personal com-
unication) and probably do not derive from a common
ncestral serpin that was present in the progenitor of the
rthopoxviruses and leporipoxviruses.
For CPV SPI-3, as for all the orthopoxvirus SPI-3 se-
uences in the databases, the predicted P1 residue
ithin the RCL is Arg. SERP1 has a signal peptide from
mino acids 1 to 15 (Fig. 1) that is not present in the
ecreted form of the protein (P. Nash and G. McFadden,
obarts Research Institute, personal communication).
nalysis of the CPV SPI-3 protein with SignalP v1.1
Nielsen et al., 1997), a program designed to identify
ignal peptides and their cleavage sites by neural net-
orks, gave a predicted signal peptide from residues 1
o 15 (Fig. 1). However, unlike SERP1, SPI-3 is not se-
reted naturally following infection with wtCPV (data not
hown) or after overexpression in vaccinia virus (Wang et
l., 2000). Although SERP1 and SPI-3 both have N-linked
lycosylation, the number and location of the potential
-glycosylation sites in the two proteins are quite differ-
nt (Fig. 1). SERP1 has three sites matching the Asn-Xaa-
er/Thr motif at positions 28, 99, and 172, but SPI-3 has
our at positions 161, 188, 232, and 242, none of which
ligns with the sites in SERP1 (Fig. 1).
omplex formation between SPI-3 and serine
roteinasesWe screened a panel of serine proteinases that cleave
fter basic amino acids (Arg, Lys) to determine whether
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269INHIBITORY SERPIN SPI-3any of them formed a stable complex with SPI-3. Com-
plexes between serpins and proteinases that can be
visualized by SDS–PAGE are a strong indication that
inhibitory interactions are occurring. Our strategy was to
use 35S-labeled unpurified SPI-3 protein and to compare
its behavior to that of SERP1 produced in a similar
manner. Purified SERP1 is known to form stable com-
plexes with and inhibit plasmin, uPA, and tPA (Lomas et
al., 1993; Nash et al., 1998). Radiolabeled SPI-3 protein
as synthesized in vitro from plasmid DNA of pTM1-
PI-3 by coupled transcription/translation using the TNT
7 Quick system (Promega). A single polypeptide of 42
Da was visible by SDS–PAGE (Fig. 2A, lane 1), close to
he expected size of 42.5 kDa for the primary translation
roduct. When SPI-3 was transcribed and translated in
he presence of canine microsomal membranes, a lad-
er of five polypeptide species was visible with sizes of
pproximately 38, 41, 43, 45, and 48 kDa (Fig. 2A, lane 2).
or each N-linked glycosylation site one expects an
ncrease in apparent size of about 1.5 to 3 kDa (Coligan
FIG. 1. Comparison of MYX SERP1 and CPV SPI-3. The proteins wer
enetics Computer Group (Madison, WI). Identical residues are indicate
imilar residues are indicated by dots, and dissimilar amino acids are
redicted signal at the corresponding position in SPI-3 are underline
hown by boxes (with rounded corners for SERP1 and rectangles for SP
ithin the RCL region from approximately P20 to P209 indicated by thet al., 1998). The observed pattern (Fig. 2A, lane 2) pre-
umably reflects incomplete glycosylation in vitro and isconsistent with the utilization of all four potential N-
glycosylation sites. The lowest band presumably repre-
sents unglycosylated SPI-3 with the signal peptide re-
moved (predicted size 41 kDa), and the four bands above
appear to have modification at one, two, three, and four
sites. The remaining experiments with radiolabeled
SPI-3 were done with material synthesized in the ab-
sence of microsomal membranes, as we were not able to
obtain fully glycosylated protein in the presence of mi-
crosomes. The interpretation of potential complexes
would have been difficult with multiple species of SPI-3,
and in addition precedents indicate that although glyco-
sylation may play an important role in maintaining ser-
pins in a stable form in plasma, it is not required for
proteinase inhibition (Potempa et al., 1994).
Radiolabeled SERP1 was tested for the ability to form
SDS-stable complexes with serine proteinases that have
a preference for cleaving after Arg or Lys. MYX SERP1
lacking the cleavable signal peptide was synthesized by
in vitro transcription/translation from pALTER-Ex1/SERP1
ed using the GAP program from the Wisconsin Package Version 10.0,
rtical lines, closely related residues are indicated by colons, somewhat
ted by gaps. The signal peptide at the N-terminus of SERP1 and the
the locations of potential N-glycosylation sites (Asn-Xaa-Ser/Thr) are
each sequence the P1 Arg residue is in boldface type and underlined,
ets.e align
d by ve
indica
d, and(Materials and Methods) and used without further puri-
fication. SERP1 produced in this system without glyco-
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270 TURNER ET AL.sylation but otherwise corresponding to the natural se-
creted form was able to form intense complexes with
plasmin, uPA, and tPA of 64, 70, and 74 kDa, respectively
(Fig. 2B, lanes 3, 4, and 5), and weaker complexes with
factor Xa (70 kDa, barely visible in lane 6) and thrombin
(74 kDa, lane 7). These results are consistent with data
reported by others (Lomas et al., 1993; Nash et al., 1998)
hat were obtained by detecting complexes between
urified SERP1 protein and proteinases by immunoblot-
ing. In each instance where a complex containing
ERP1 was seen, there was some accompanying cleav-
ge of SERP1 (dashed arrow in Fig. 2B), presumably
FIG. 2. Similar formation of proteinase complexes by SERP1 and SP
transcription/translation in vitro in the absence (lane 1) and in the pres
ranslation mix), and the reaction products were analyzed by SDS–PA
ndicating incomplete glycosylation. (B) SERP1 synthesized in vitro w
hosphate, pH 7.4, 160 mM NaCl, 0.1% polyethylene glycol 4000) (Loma
, untreated SERP1; lane 2, SERP1 incubated without enzyme; lane 3, w
.5 mM factor Xa; lane 7, 0.5 mM thrombin; lane 8, 1 mM tissue kallikrein;
by the solid arrow, and the area where complexes migrate is marked b
Radiolabeled SPI-3 from in vitro transcription/translation was incubated
The proteinases used are indicated above the lanes, and complexes a
SPI-3 in this minigel. (D) Section of a large-format (16 3 16 cm) 10% a
proteinases as in C. Uncleaved and cleaved SPI-3 are indicated by the s
occurred is not shown.ithin the RCL. With tissue kallikrein, SERP1 was
leaved and produced no visible complex formation (Fig.
S
rB, lane 8). In the case of complement C1s there was no
vidence for either cleavage or complex production (Fig.
B, lane 9). The ability to detect stable complexes be-
ween 35S-labeled SERP1 and proteinases by SDS–PAGE
uggests that SERP1 protein synthesized without the
ignal peptide in the absence of canine microsomal
embranes is fully active as an inhibitor.
SPI-3 with the predicted signal peptide was expressed
y coupled in vitro transcription/translation and tested
or complex formation with the same set of proteinases.
ach proteinase was incubated for 30 min at 37°C with
PI-3, using a fixed amount of unpurified 35S-labeled
thesized in vitro. (A) Radiolabeled SPI-3 protein was made by coupled
lane 2) of canine microsomal membranes (2 ml microsomes per 20 ml
d autoradiography. Note the ladder of five protein species in lane 2
ubated with various proteinases in universal buffer (30 mM sodium
., 1993), and the reaction products were analyzed by SDS–PAGE. Lane
0 nM pig plasmin; lane 4, with 25 nM uPA; lane 5, 100 nM tPA; lane 6,
1 mM complement C1s. The position of the unreacted SERP1 is marked
racket. The dashed arrow indicates the position of cleaved SERP1. (C)
oteinases as in B and analyzed on a 10% acrylamide 6 3 8 cm minigel.
cated by the bracket. Cleaved SPI-3 is not separated from uncleaved
ide gel used to resolve the reaction products after treating SPI-3 with
d dashed arrows, respectively. The area of the gel in which complexesI-3 syn
ence (
GE an
as inc
s et al
ith 10
lane 9,
y the b
with pr
re indi
crylamPI-3 protein from the TNT T7 Quick system and a wide
ange of proteinase concentrations. The results indi-
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271INHIBITORY SERPIN SPI-3cated that SPI-3 gave strong slow-migrating bands with
plasmin, uPA, and tPA (Fig. 2C, lanes 3, 4, and 5, respec-
tively) and weaker bands with both factor Xa and throm-
bin (lanes 6 and 7, respectively). All of the enzymes that
SPI-3 gave complexes with also gave some cleavage of
SPI-3 (Fig. 2D). The sizes of the putative complexes (Fig.
2C) were approximately what would be expected from
the sum of RCL-cleaved SPI-3 (38.8 kDa) and the size of
the catalytic subunit of the proteinase in question. The
observed sizes of complexes with SPI-3 were as follows:
for plasmin, 66 kDa; for uPA, 68 kDa; for tPA, 75 kDa; for
factor Xa, 66 kDa; and for thrombin, 70 kDa. The relative
sizes of the complexes with SPI-3 (Fig. 2C) were very
similar to those seen for the complexes involving SERP1
(Fig. 2B). No complexes were detected between SPI-3
and either tissue kallikrein or C1s (Fig. 2C, lanes 8 and
9). SPI-3 cleavage was observed with kallikrein but not
with C1s (Fig. 2D, lanes 8 and 9). The occurrence of
SPI-3/proteinase complexes (Fig. 2C) suggests that
SPI-3 is capable of acting as a proteinase inhibitor.
Moreover the pattern of complex formation and cleavage
FIG. 3. Site-directed mutants in the SPI-3 RCL are unable to form c
region of wt SPI-3 and the P1/P19, P5/P59, and P17/P10 site-directed m
of radiolabeled wt and mutant SPI-3 proteins treated with plasmin. Lan
and lanes 2, 4, 6, and 8 show the same proteins following incubation w
arrow. (C) Wt and mutant SPI-3 treated with uPA. Lanes 1, 3, 5, and 7 sh
uPA, with the wt SPI-3/uPA complex shown by the arrow. (D) Incubation
and lanes 2, 4, 6, and 8 show proteins incubated with tPA. The arrowwith the proteinases tested was identical for SERP1 (Fig.
2B) and for SPI-3 (Fig. 2CD).
S
cSPI-3 RCL mutants are unable to form stable
complexes with plasmin, uPA, or tPA
An examination of the SPI-3 RCL sequence (Fig. 1)
together with the fact that SPI-3 is able to complex with
plasmin, uPA, and tPA (Fig. 2C) strongly suggests that the
residue responsible for covalent linkage is Arg-340 at the
P1 position. The arginine at this position aligns with the
P1 residues of inhibitory serpins, including SERP1 (Fig.
1). In order to test the hypothesis that Arg-340 was
required for complex formation, we assessed the ability
of preexisting site-directed mutants in SPI-3 (Turner and
Moyer, 1995) to form complexes with plasmin, uPA, and
tPA. The mutants used were P1/P19, in which Arg-Ser at
positions 340/341 had been changed to Gly-Ala (Fig. 3A),
and P5/P59, in which the 10 amino acids from the P5 to
P59 positions were replaced (Fig. 3A). The P5/P59 mutant
as created by deleting a single base from the P5 codon
nd inserting a single base after the P59 codon, thus
rameshifting the region after P5 and restoring the wild-
ype reading frame after P59. The P1/P19 and P5/P59
es with plasmin, uPA, and tPA. (A) Amino acid sequences of the RCL
. Residues altered in the mutants are shown in italics. (B) SDS–PAGE
5, and 7 show wt, P1/P19, P5/P59, and P17/P10 SPI-3 without plasmin,
smin. The complex between wt SPI-3 and plasmin is indicated by the
reated proteins, and lanes 2, 4, 6, and 8 show proteins incubated with
nd mutant SPI-3 with tPA. Lanes 1, 3, 5, and 7 show untreated samples
the position of the wt SPI-3/tPA complex.omplex
utants
es 1, 3,
ith pla
ow untPI-3 mutant proteins were synthesized in vitro and in-
ubated with plasmin, uPA, or tPA, and the reaction
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272 TURNER ET AL.products were analyzed by SDS–PAGE. Under these con-
ditions, wt SPI-3 gave clear evidence of complex forma-
tion with each proteinase (arrow in Figs. 3B, 3C, and 3D),
but no complexes were visualized between either the
P1/P19 or the P5/P59 mutant and plasmin (Fig. 3B), uPA
(Fig. 3C), or tPA (Fig. 3D). The loss of complex formation
resulting from the alteration of Arg-340/Ser-341 in the
P1/P19 mutant strongly suggests that the proteinases
initially attack the scissile bond following Arg-340 in wt
SPI-3.
A small, uncharged residue at the P14 position is
required in inhibitory serpins to enable insertion of the
RCL into the body of the serpin and hence formation of a
stable serpin/proteinase complex (Potempa et al., 1994).
The hypothesis that loop insertion of SPI-3 is required for
inhibition was tested by studying the P17/P10 mutant,
where residues 324–331 of wt SPI-3, including the pre-
dicted P14 residue at Thr-327, have been replaced (Fig.
3A). P17/P10 was generated by inserting a base at the
P17 codon and deleting a base after the P10 codon, thus
frameshifting the codons for P17 to P10. Despite the
retention of Arg-340 at the P1 position in this mutant, we
would expect that the P17/P10 mutant protein would act
as a substrate rather than an inhibitor. 35S-labeled P17/
10 SPI-3 protein was unable to complex with plasmin,
PA, or tPA (Figs. 3B–3D), suggesting that the small
ncharged amino acids within the proximal hinge region
f wt SPI-3 are indeed required for serpin activity. Taken
ogether, the results with the SPI-3 RCL mutants indicate
hat residues in this region are important for complex
ormation with plasmin, uPA, and tPA.
omplex formation between SPI-3 and plasmin does
ot occur in the presence of a2-antiplasmin
If the SPI-3/plasmin complex results from pseudo-
substrate activity of SPI-3, we would expect that the
formation of the complex would be blocked by a natural
serpin inhibitor of plasmin. We therefore incubated fixed
amounts of radiolabeled SPI-3 (1 ml TNT product) and
lasmin (50 ng) with varying amounts of a2-antiplasmin
nd assessed the degree of complex formation by SDS–
AGE. The results show that the intensity of the SPI-3/
lasmin complex marked by the arrow decreases pro-
ressively as the amount of a2-antiplasmin increases
Fig. 4A, lanes 2–7). The proportion of radioactivity in
ach lane migrating at the position of the complex was
etermined by PhosphorImager analysis and in Fig. 4B is
lotted against the amount of a2-antiplasmin present,
clearly indicating that a2-antiplasmin competes effi-
ciently with SPI-3 for binding to plasmin. These results
exclude the possibility that SPI-3 is complexing with
plasmin through a secondary binding site distant from
the active site. Locking plasmin into a stable complex
with SPI-3 would prevent the enzyme from cleaving a
synthetic peptide substrate. We decided to express andpurify SPI-3 protein in order to test directly for inhibition
of plasmin and the other enzymes that complex with
SPI-3.
Purification and inhibitory properties of SPI-3
expressed by the vaccinia/T7 system
The quantities of SPI-3 synthesized naturally early in
CPV infection are minimal as judged by Western blotting
(Turner and Moyer, 1995), and we therefore made use of
the vaccinia/T7 expression system to produce larger
quantities. Initially we fused a His10-tag to the extreme
N-terminus of the SPI-3 protein to facilitate purification by
immobilized metal affinity chromatography. The total pro-
teins expressed by the vaccinia/T7 system in CV-1 cells
were radiolabeled and analyzed by SDS–PAGE (Figs. 5A
and 5B). Coinfection with vTF7-3 expressing the T7 RNA
FIG. 4. Antiplasmin prevents formation of a complex between SPI-3
and plasmin. (A) 35S-labeled SPI-3 from in vitro transcription/translation
was incubated for 30 min at 37°C in the presence of a fixed amount of
plasmin and with varying amounts of a2-antiplasmin (Athens Research
nd Technology, Inc., Athens, GA). Lane 1, untreated SPI-3 incubated in
lasmin buffer. Lane 2, SPI-3 incubated with plasmin and without
a2-antiplasmin. Lanes 3–7, SPI-3 incubated with plasmin and with 10,
50, 100, 250, or 500 ng a2-antiplasmin, respectively. The position of the
SPI-3/plasmin complex is indicated by the arrow. (B) Quantification of
the radioactivity in the complex band by PhosphorImager analysis. The
complex intensity is expressed as the percentage of the total radioac-
tivity in each lane migrating at the position of the arrow and is plotted
as a function of added a2-antiplasmin.polymerase and a VV recombinant containing the wt
SPI-3 gene downstream from the T7 promoter gave SPI-
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273INHIBITORY SERPIN SPI-33-derived bands of approximately 42, 48, and 50 kDa (Fig.
5A, lane 3), as described previously (Turner and Moyer,
1995), with the largest two bands being glycosylated
forms of SPI-3. Expression of the entire SPI-3 protein with
a His10-tag at the N-terminus (Fig. 5A, lane 4) produced
proteins of approximately 45, 48, and 50 kDa. The lowest
band of the triplet was presumably the primary transla-
tion product His-SPI-3, which has a calculated molecular
mass of 45.3 kDa. However, following adsorption of the
proteins to His-Bind resin and elution, it was clear that
only the smallest of the three radiolabeled bands still
retained the His10-tag (data not shown). Presumably the
His10-tag was removed together with the SPI-3 signal
eptide, and then the mature form of SPI-3 was glycosy-
ated as for wt SPI-3 (compare lanes 3 and 4 in Fig. 5A).
By deleting the sequence from residues 1 to 15 en-
oding the predicted signal peptide, we were able to
xpress a form of SPI-3 that retained the N-terminal
is-tag. As expected, expression in CV-1 cells of His-
PI-3DS lacking the signal peptide gave a single radio-
abeled protein that migrated at 44 kDa (Fig. 5B, lane 6),
lose to the calculated size of 43.7 kDa for the primary
ranslation product in the absence of N-linked glycosyl-
tion. Proteins of higher molecular mass derived from
is-SPI-3DS were absent (Fig. 5B, lane 6), indicating that
he removal of the signal peptide prevented N-linked
lycosylation, as predicted. The resulting radiolabeled
is-SPI-3DS protein adsorbed to His-Bind resin, showing
FIG. 5. Expression of His10-tagged forms of the SPI-3 protein with a
nfection of CV-1 cells with vaccinia derivatives were labeled with [35S]m
utoradiography. Lane 1, uninfected CV-1 cells; lane 2, infected with v
PI-3); lane 4, vTF7-3 1 VV-His-SPI-3 (tagged entire SPI-3 protein). The
y asterisks. The arrow indicates the position of the unglycosylate
nglycosylated wt SPI-3 protein. (B) Radiolabeled proteins synthesized b
tagged entire SPI-3 protein), as in lane 4 of A; lane 6, vTF7-3 1 VV-His
crylamide–SDS gel showing the quality of purified His-tagged SPI-3 pr
staining; lane 2, 2 mg SPI-3 protein detected by Coomassie staining.hat the N-terminal His10 tag remained attached.
His-tagged SPI-3 lacking the signal peptide was puri-fied to near homogeneity based on silver staining and
Coomassie staining of an acrylamide–SDS gel (Fig. 5C,
lanes 1 and 2, respectively). Purified SPI-3 protein was
then tested for the ability to inhibit plasmin, uPA, tPA,
factor Xa, and thrombin in enzymatic assays. A fixed
amount of each enzyme (approximately 2–3 pmol) was
chosen based on the ability to give an observed change
in optical density of approximately 0.02 OD units per
minute in the absence of inhibitor. The results (Fig. 6)
show that recombinant SPI-3 protein is an effective in-
hibitor of plasmin, uPA, and tPA, with almost complete
inhibition observed at levels of SPI-3 protein above 1 mg.
In contrast, only partial inhibition of factor Xa activity was
observed (Fig. 6), with approximately 50% residual activ-
ity even at the highest level of SPI-3 protein tested (5 mg
SPI-3 protein in a volume of 50 ml). Purified SPI-3 protein
esulted in only a very slight inhibition of thrombin (Fig.
). The extent of inhibition of plasmin, uPA, and tPA by
urified SPI-3 protein (Fig. 6) was consistent with the
ntensity of the complexes detected between radiola-
eled SPI-3 protein and these proteinases (Fig. 2C).
PI-3 was a functional inhibitor of plasmin, uPA, and tPA
nd gave a strong complex with each of these enzymes
n vitro.
etermination of kinetic parameters for SPI-3 against
lasmin, uPA, and tPA by progress curve analysis
out the predicted signal sequence. (A) Proteins synthesized following
ine and analyzed by electrophoresis on 10% acrylamide–SDS gels and
xpressing T7 RNA polymerase; lane 3, vTF7-3 1 VV-SPI-3 (untagged
her molecular mass SPI-3 derived bands in lanes 3 and 4 are marked
PI-3 protein in lane 4, and the “o” migrating slightly faster is the
accinia-T7 system in CV-1 cells, as in A. Lane 5, vTF7-3 1 VV-His-SPI-3
S lacking the signal peptide from residues 1 to 15 in wt SPI-3. (C) 10%
cking the signal peptide. Lane 1, 2 mg SPI-3 protein visualized by silvernd with
ethion
TF7-3 e
two hig
d His-S
y the v
-SPI-3DWe made measurements of the inhibition constant (K i)
and the association rate constant (k a) for SPI-3 when
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274 TURNER ET AL.reacted with plasmin, uPA, and tPA in order to compare
the kinetic parameters of SPI-3 with the published values
for SERP1 (Nash et al., 1998). The progress curve method
as used with conditions for slow-binding inhibition. A
ixed low concentration of enzyme was added to mix-
ures containing substrate and varying concentrations of
PI-3 inhibitor. The increase in absorbance generated by
ubstrate cleavage was followed over a period of 14 h.
epresentative progress curves from incubating SPI-3
nd plasmin together are shown in Fig. 7A. In the ab-
ence of inhibitor, the rate of substrate cleavage was
inear for the duration of the assay (Fig. 7A, curve a).
hen SPI-3 was added, the rate of hydrolysis decreased,
nd the final absorbance was lower with increasing
oncentrations of SPI-3 (Fig. 7A, curves b–f). From plot-
ing curves c through f from Fig. 7A on a different scale
Fig. 7B), the curvature becomes more evident. The initial
elocity decreases exponentially with time, finally
eaching a steady-state velocity. The curves in Fig. 7B
ere fitted to the data points using the equation
At 5 vst 1
v i 2 vs
k
~1 2 e 2kt! 1 d,
and illustrate how well the model describes the binding
of SPI-3 to plasmin at low concentrations. Note that the
final linear rate of substrate cleavage decreased with
increasing concentration of SPI-3. Figure 7C was ob-
FIG. 6. Effect of purified SPI-3 protein on the enzymatic activity of pla
Materials and Methods for details) was preincubated with different am
amount of residual active enzyme was determined by addition of the app
was monitored by an increase in absorbance at 405 nm, and the rate w
activity vs the amount of SPI-3 added during the preincubation, with thtained by plotting proportional activity, i.e., the final ve-
locity vs divided by the initial (uninhibited) velocity v i, asa function of the initial SPI-3 concentration I 0. The sub-
strate-dependent inhibition constant K i(app) was derived
y fitting Eq. (2) to the data by nonlinear regression as
escribed under Materials and Methods. The final sub-
trate-independent value of K i (0.64 nM for plasmin from
he average of two experiments) was obtained from the
ormula K i 5 K i(app)/(1 1 S/K m) by using the experimen-
tally determined value of K m and the initial concentration
of substrate S present in the experiment. For plasmin,
uPA, and tPA, the progress curve analysis was performed
twice, and the resulting K i values are listed in Table 1.
The mean K i values for SPI-3 against plasmin, uPA, and
tPA were 0.64, 0.51, and 1.9 nM, respectively, in compar-
ison with inhibition constants for SERP1 of 0.44, 0.16, and
0.14 nM, respectively (Nash et al., 1998). The values of K i
for SPI-3 were comparable to the values for SERP1
against the same enzymes (Table 1).
The apparent association rate constant k, which de-
scribes how quickly the transition is made from the initial
(uninhibited) velocity to the final steady-state velocity,
was determined for each concentration of plasmin. A plot
of k vs the SPI-3 concentration I 0 is represented in Fig.
D. From the slope, the substrate-independent associa-
ion rate constant k a for SPI-3 with plasmin was esti-
ated at 6.9 3 104 M21s21 (mean of two independent
experiments). k a values for SPI-3 against uPA and tPA
were determined in a similar manner, with a complete
PA, tPA, factor Xa, and thrombin. A fixed quantity of each enzyme (see
of purified SPI-3 protein for 30 min at room temperature, and then the
e peptide substrate conjugated to p-nitroanilide. Cleavage of substrate
rmined. The results are expressed as the proportional rate of enzyme
in the absence of added SPI-3 protein set at 1.smin, u
ounts
ropriatset of progress curves done in duplicate. The values
obtained for SPI-3 against plasmin, uPA, and tPA are
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275INHIBITORY SERPIN SPI-3compared with the corresponding association rate con-
stants for SERP1 (Nash et al., 1998) and are quite similar
(Table 1). The k a values for SPI-3 ranged from 3.3 3 10
4
M21s21 for tPA to 1.2 3 105 M21s21 for uPA and are at or
ust below the threshold of 105 M21s21 that is thought to
e adequate for possible physiological significance (Tra-
is and Salvesen, 1983). Based on this analysis, SPI-3 is
good inhibitor of plasmin, uPA, and tPA and appears
FIG. 7. Progress curve analysis of inhibition of plasmin by SPI-3. (A) P
a fixed quantity of plasmin in the presence of different concentration
comparison of the progress curves obtained. Curve a (plasmin alone
experiment and that substrate depletion does not occur. Curve b is in
g SPI-3, curve d is with 50 ng, curve e is with 80 ng, and curve f is w
he curve fitted using Eq. (1) described under Materials and Methods.
as a function of inhibitor amount. The curve was obtained from Eq. (2)
k as a function of SPI-3 amount. The slope is directly proportional to tikely to inhibit a cellular proteinase in vivo during or-
hopoxvirus infection.
t
(DISCUSSION
SPI-3 has previously been shown to inhibit infected
ell fusion (Law and Smith, 1992; Turner and Moyer,
992; Zhou et al., 1992) via a mechanism that does not
epend on motifs within the serpin RCL (Turner and
oyer, 1995). Here we show that SPI-3 is also capable of
cting as a proteinase inhibitor. Radiolabeled SPI-3 pro-
wing the increase of absorbance with cleavage of substrate S2251 by
I-3. The initial absorbance has been normalized to zero to facilitate
ear and shows that the enzyme is stable during the duration of the
sence of 10 ng SPI-3 protein in 200 ml total volume, curve c is with 30
ng. (B) Replot of curves c through f from (A), showing data points and
at the final rates are linear. (C) Plot of proportional plasmin rate (vs/v i)
aterials and Methods. (D) Plot of observed association rate constant
ociation rate constant k a.lot sho
s of SP
) is lin
the pre
ith 200
Note thein synthesized in vitro that lacks N-linked glycosylation
Fig. 2A) is able to form strong complexes with plasmin,
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276 TURNER ET AL.uPA, and tPA (Fig. 2C), indicating that glycosylation is not
required for complex formation. Similarly, SPI-3 protein
that was expressed in cells without the signal peptide
and purified was active as an inhibitor (Fig. 6), although
N-linked carbohydrate modification was again appar-
ently not present (Fig. 5B). These data are consistent
with published results for mammalian serpins, where
glycosylation is not required for proteinase inhibition per
se, but may have profound effects on the stability of
serpins in vivo (Potempa et al., 1994). We tested SPI-3
protein synthesized by in vitro transcription/translation in
the presence of microsomes for the ability to complex
with plasmin and found that the glycosylated forms of the
protein formed complexes in a manner similar to that
seen for the unglycosylated protein (data not shown).
Although proteinase inhibition by SPI-3 does not require
glycosylation, the other activity of SPI-3, namely, inhibi-
tion of cell–cell fusion, may be dependent on glycosyla-
tion. Experiments are in progress to test this hypothesis
directly by site-directed mutagenesis of the four potential
N-linked glycosylation sites in SPI-3 (Fig. 1).
The use of unpurified SERP1 protein from in vitro
transcription/translation to assess complex formation
gave results with proteinases (Fig. 2B) that were com-
pletely consistent with those using purified SERP1 pro-
tein from expression in vaccinia virus (Nash et al., 1997,
1998). The fact that the radiolabeled protein was present
with high concentrations of unlabeled rabbit reticulocyte
proteins in the TNT reaction products facilitated detec-
tion of complexes, which were observed at a wide range
of proteinase concentrations (data not shown). In con-
trast, the use of purified serpin protein for complex de-
tection requires careful titration of enzyme, as excess
proteinase can result in proteolytic cleavage of the com-
plex (Nash et al., 1998). Our results with SERP1 protein
ynthesized in vitro were also in agreement with data
obtained using secreted SERP1 protein in MYX superna-
tants (Lomas et al., 1993), with the exception that we did
ot observe a complex between complement C1s and
ERP1. The C1s/SERP1 complex originally reported us-
T
Kinetic Parameters for SP
Enzyme
Inhibition constant K i (nM)
SPI-3
SERP1aExp. 1 Exp. 2 Average
Plasmin 0.58 0.69 0.64 0.44 6 0.05
uPA 0.28 0.74 0.51 0.16 6 0.01
tPA 1.47 2.33 1.9 0.14 6 0.02
a Data from Nash et al. (1998).ng unpurified supernatants (Lomas et al., 1993) was not
ound when purified SERP1 protein was examined (Nash
e
rt al., 1997, 1998), although weak inhibition of comple-
ent C1s by SERP1 protein was noted in enzymatic
ssays (Nash et al., 1998).
The occurrence of a complex between SPI-3 and plas-
min, uPA, or tPA was abolished by substitution at the P1
and P19 positions (Fig. 3), providing good evidence that
in each case Arg-340 is required for complex formation.
a2-antiplasmin effectively blocked complex formation be-
tween SPI-3 and plasmin (Fig. 4), suggesting that SPI-3
was interacting with plasmin via its active site. In our
experience, the intensity of the complex observed be-
tween a given proteinase and SPI-3 (Fig. 2C) was a good
predictor of the extent of inhibition by purified protein
(Fig. 6). With factor Xa, a weak complex was seen to-
gether with relatively poor inhibition of enzymatic activity.
For thrombin, a weak complex with SPI-3 was seen in the
presence of a high concentration of enzyme, but little or
no inhibition was observed. The lack of thrombin inhibi-
tion observed in our assay may reflect a high stoichiom-
etry of inhibition; i.e., several molecules of SPI-3 may be
required to inhibit each thrombin molecule due to parti-
tioning into the cleavage pathway. SERP1 has been re-
ported to have a high stoichiometry of inhibition for
thrombin of 13 6 3 (Nash et al., 1998). However, in kinetic
terms SERP1 is an effective inhibitor of thrombin (Nash et
al., 1998) and gives complete inhibition of thrombin, un-
like SPI-3 (Fig. 6).
Kinetic parameters for the equilibrium dissociation
constant K i and the association rate constant k a were
quite similar for SPI-3 and SERP1 against plasmin, uPA,
and tPA. Our values for SPI-3 were made assuming that
100% of the purified His-tagged SPI-3DS protein was
active as an inhibitor and therefore may underestimate
the ability of SPI-3 to act as an inhibitor. The calculations
of k a were derived assuming that the association be-
ween SPI-3 and enzyme is a simple one-step process, in
rder to facilitate comparison with published data for
ERP1 (Nash et al., 1998). However, closer examination
f our association rate data for SPI-3, especially for
lasmin, suggested that a two-step mechanism was in
th Plasmin, uPA, and tPA
Association rate k a (M
21 s21)
SPI-3
SERP1aExp. 1 Exp. 2 Average
.9 3 104 4.9 3 104 6.9 3 104 4.8 6 0.5 3 104
.8 3 105 6.1 3 104 1.2 3 105 5.0 6 0.6 3 104
.0 3 104 2.6 3 104 3.3 3 104 4.3 6 0.4 3 104ABLE 1
I-3 wi
8
1
4ffect, with a hyperbolic dependence of the observed
ate constant k on the inhibitor concentration (Bieth,
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277INHIBITORY SERPIN SPI-31995). A two-step process suggests the formation of a
loose intermediate SPI-3/plasmin complex preceding the
tight inhibitory complex and has been described for other
serpins such as antithrombin and protease nexin I with
thrombin (Stone and Hermans, 1995). The overall simi-
larity between the inhibitory profiles of SPI-3 and SERP1
(Figs. 2B, 2C, and 6, Table 1) is remarkable considering
the degree of sequence divergence between the two
poxvirus serpins (Fig. 1) and raises the question as to
whether the natural proteinase targets for the two inhib-
itors are identical. Experiments to address this point are
described in the following paper (Wang et al., 2000).
Although SPI-3 does function as a proteinase inhibitor
in addition to its role in controlling cell–cell fusion, any
assumption that plasmin, uPA, and tPA are natural tar-
gets of SPI-3 following orthopoxvirus infection should be
viewed with caution. These serine proteinases are
present in plasma at very high concentrations, but would
not be expected to encounter SPI-3, which is associated
with infected cells rather than being secreted into the
extracellular environment. Future work is directed toward
detecting a complex between SPI-3 and a proteinase in
vivo, with the ultimate goal of identifying the natural
target proteinase for SPI-3.
MATERIALS AND METHODS
Viruses and cells
CPV strain Brighton Red and MYX strain Lausanne
were originally obtained from Dr. David Pickup (Duke
University) and Dr. Grant McFadden, (Robarts Research
Institute, London, Ontario, Canada), respectively, and
were propagated and titered on CV-1 (CPV) or RK-13
(MYX) cells.
Plasmid constructions
pBluescript-SPI-3, pTM1-SPI-3, and the P1/P19, P5/P59,
and P17/P10 site-directed SPI-3 mutants have been de-
scribed previously (Turner and Moyer, 1995). The SERP1
ORF without the signal peptide from residues 1 to 15 (P.
Nash and G. McFadden, personal communication) and
with a Met codon added at the new N-terminus was
PCR-amplified from genomic MYX DNA using primers
GM25 (59-GGAATTCATGAGAGATATCGGACTATGG-39,
EcoRI site underlined) and GM26 (59-CTGGATCCTC-
GAGTTATACAGAGGATACGACATC-39, BamHI site under-
lined) against the 59 and 39 ends of the SERP1 ORF,
respectively. The PCR product was inserted into pALTER-
Ex1 (Promega) to create pALTER-Ex1/SERP1, thus en-
abling expression in vitro from the T7 promoter. pTM1-
His-SPI-3 was constructed by inserting the entire SPI-3
ORF into pTM1-His (Takahashi et al., 1996), a derivative
of pTM1 (Moss et al., 1990) carrying the His10-tag from
pET-16b. The signal peptide for SPI-3 was predicted by
the SignalP v1.1 program (Nielsen et al., 1997) to extend efrom residues 1 to 15. Oligonucleotides FS82 (59-GGAT-
TAGCATATGTATCGTCTGCAAGGATTTACC-39, NdeI site
underlined) and RM138 (Turner and Moyer, 1995) were
used to PCR-amplify the SPI-3 ORF without the putative
signal peptide (SPI-3DS). An 867-bp NdeI fragment from
he PCR product extending from the FS82 region to a
atural NdeI site at position 909 of the SPI-3 ORF was
loned into pTM1-His-SPI-3 in place of the correspond-
ng fragment from wt SPI-3 to create pTM1-His-SPI-3DS.
ssays for complex formation using radiolabeled
erpins
35S-labeled SERP1 and SPI-3 proteins were synthe-
sized by transcription and translation in vitro from the
plasmid DNAs pALTER-Ex1/SERP1 and pTM1-SPI-3, re-
spectively, using the TNT T7 Quick system (Promega).
The reaction products were incubated without further
purification with proteases in a total volume of 12 ml
buffer for 30 min at 37°C and then tested for cleavage
and complex formation by electrophoresis in 10% acryl-
amide–SDS gels. Radioactive proteins were visualized
by autoradiography following treatment with Amplify
(Amersham Pharmacia Biotech).
Pig plasmin and human plasmin were from Sigma and
from Athens Research and Technology, Inc., respectively,
and were incubated with TNT products in plasmin buffer:
10 mM potassium phosphate, 70 mM sodium phosphate,
100 mM lysine, pH 7.5. uPA from human kidney (Sigma)
was used in 60 mM Tris–HCl, pH 7.5, 90 mM NaCl. Pig
tissue kallikrein (Sigma) was used in 50 mM Tris–HCl,
pH 8.0, 100 mM NaCl. For other enzymes, the sources
and buffers used were as follows: two-chain tPA from
cultured human melanoma cells and trypsin (both from
Sigma), 50 mM Tris–HCl, pH 8.0, 100 mM NaCl; thrombin
(Sigma), 50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 2.5 mM
CaCl2; complement C1s (Sigma), 100 mM sodium phos-
phate, 100 mM NaCl, 15 mM EDTA, pH 8.0; factor Xa
(Sigma), 20 mM Tris, pH 8.0, 100 mM NaCl, 2 mM CaCl2;
and cathepsin G (ART), 100 mM Tris–HCl, pH 8.0, 10 mM
CaCl2.
solation of recombinant viruses
VV derivatives containing His-tagged SPI-3 inserted
nto the thymidine kinase (TK) gene were obtained by
ransfecting pTM1-His-SPI-3 (with or without the signal
eptide) together with genomic wtVV DNA into CV-1 cells
nfected with a VV mutant dependent on isatin-b-thio-
semicarbazone (IBT) for growth and selecting for TK2
plaques on Rat2 cells in the presence of 5-bromo-29-
deoxyuridine and the absence of IBT (Fathi et al., 1986;
urner et al., 1989).
urification of His-tagged SPI-3His-SPI-3 protein lacking the signal peptide was over-
xpressed following coinfection of suspension HeLa
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278 TURNER ET AL.cells with vTF7-3 (Fuerst et al., 1986) expressing the T7
RNA polymerase and with VV-His-SPI-3DS, each at a
multiplicity of 5. At 18 h postinfection the infected cells
were pelleted, washed in PBS, and swollen in hypotonic
buffer (20 mM Tris–HCl, pH 8.0, 10 mM NaCl, 1 mM
PMSF) on ice for 5 min. Following dounce homogeniza-
tion, 1/15 vol 5 M NaCl and 1/10 vol 100% glycerol were
added, and the extract was held on ice for 15 min before
centrifugation. His-SPI-3DS was purified from the
cleared lysate by immobilized metal affinity chromatog-
raphy (Ausubel et al., 1987) using His-Bind resin (Nova-
en). Column fractions containing the His-SPI-3DS pro-
ein were pooled and concentrated, and the final protein
oncentration was measured by the Bradford assay.
nzymatic assays for residual activity following
reincubation with serpin
Enzyme and SPI-3 were preincubated for 30 min at
oom temperature in 50 ml of 50 mM Tris–HCl, pH 8.0,
100 mM NaCl; 150 ml of the same buffer containing
substrate was added, and the change in optical density
at 405 nm was followed over 40 min using a Tecan
SpectraFluor microplate reader. The following pNA chro-
mogenic substrates were used, with the final concentra-
tion indicated: plasmin, S2251 at 0.4 mM; uPA, S2444 at
0.16 mM; tPA, S2288 at 2 mM; factor Xa, S2288 at 1 mM.
For thrombin the fluorogenic substrate N-p-tosyl-Gly-Pro-
Arg-AMC was used at a final concentration of 0.1 mM,
with cleavage detected by excitation at 380 nm and
emission at 460 nm.
Kinetic analysis by the progress curve method
Enzyme was added to a mixture of SPI-3 and the
appropriate pNA substrate, and the increase in absor-
bance at 405 nm was followed at 25°C for a period of
50,700 s (14 h) with readings every 60 s for the first 30
min and then at 300-s intervals. The data were collected
with a Tecan SpectraFluor microplate reader with WinS-
elect v2.2 software using a 96-well plate, with a total
volume of 200 ml in each well. The buffer was 50 mM
Tris–HCl, pH 8.0, 100 mM NaCl with 0.25 mg/ml bovine
serum albumin added to stabilize the enzyme. A low
concentration of enzyme was chosen so that in the
absence of inhibitor, the rate of substrate cleavage was
linear throughout the 14-h incubation. The K m of each
nzyme for its substrate was determined experimentally
nder the same conditions by using the Michaelis–Men-
en equation and nonlinear regression. For plasmin and
2251, the K m was 1.2 mM; for uPA and S2444, K m 5 0.11
mM; for tPA and S2288, K m 5 0.23 mM. The concentra-
tions of substrate used in the progress curves were as
follows: for plasmin, 0.4 mM S2251; for uPA, 0.16 mM
S2444; and for uPA, 0.25 mM S2288.For each experiment the initial concentration of serpin
was in excess of the initial concentration of enzyme. Therate of substrate cleavage by uninhibited enzyme was
determined in triplicate, and progress curves were ob-
tained with SPI-3 at 15 different concentrations. The
increase in absorbance is described by
At 5 vst 1
v i 2 vs
k
~1 2 e 2kt! 1 d, (1)
in which A t is the absorbance at time t, v i is the initial
rate of substrate hydrolysis, vs is the final steady-state
elocity, k is the association rate constant, and d is the
absorbance at t 5 0. Values for v i, vs, and k were
etermined by nonlinear regression analysis with Delta-
raph 4.0 (Delta Point Inc.). The apparent inhibition con-
tant K i(app) was derived from the final linear rates of
substrate cleavage. Proportional activity (vs/v i) was plot-
ed against the initial concentration of SPI-3 (I 0), and a
curve was fitted by nonlinear regression using the for-
mula
vs
v i
5 12
~E0 1 I0 1 K iapp! 2 @~E0 1 I0 1 K iapp!
2 2 4E0I0#
1/2
2E0
, (2)
where E 0 and I 0 are the initial concentrations of enzyme
nd inhibitor, respectively (Bieth, 1995). This equation
akes into account the concentration of inhibitor bound to
he enzyme, in contrast to the formula for classical inhib-
tors, which assumes that the concentration of bound
nhibitor is negligible compared with the concentration of
otal inhibitor I 0. A value for K i(app) was determined by
onlinear regression. From this the substrate-indepen-
ent equilibrium dissociation constant, K i was deter-
ined using the formula K i 5 K i(app)/(1 1 S/K m), where
a is the initial substrate concentration.
The observed association rate constant k was deter-
ined at different levels of SPI-3 protein in cases where
he inhibitor concentration was at least 10-fold greater
han the enzyme concentration. Under these conditions k
s the pseudo-first-order rate constant for the approach
o steady state. For a simple one-step mechanism for
nzyme-inhibitor binding, E 1 I
ka
kd^
EI, the observed
association rate constant k is a linear function of the
inhibitor concentration I 0, k 5 k aI 0/(1 1 S/K m) 1 k d.
By plotting k vs I 0, the slope gives k a/(1 1 S/K m) and
hence k a.
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